Chief Technology Officer
(CTO)
Ethan Shen, PhD
CTO of SL BIO;
Founder, Chairman & CEO —
YD Bio, JY BioMed, and EG BioMed
Dr. Ethan Shen is a scientist and biotech professional with over two decades of experience in translational medicine, new drug development, and medical-grade health product innovation.
As Chief Technology Officer of SL Bio, he brings deep scientific expertise to support the company's research direction and technology development.
His background spans oncology diagnostics, exosome-based research, and collaborative drug development initiatives, including participation in an anti–PD-L1 cancer vaccine project in partnership with the University of Southern California.
At SL Bio, Dr. Shen remains dedicated to advancing science-based solutions that drive meaningful innovation.
Academic Excellence
PhD in Translational Medicine (2024)
Academia Sinica & Taipei Medical University (Top 250 in Clinical and Health studies).
EMBA (2016)
Fudan University (Global Rank: 36) & National Taiwan University (Global Rank: Top 125 in Business and Economics).
Graduate Certificate in Financial Research (2006)
City University of New York, Baruch College.
Bachelor of Pharmacy (2000)
Taipei Medical University.
Professional Achievements
-
Over two decades of experience in biomedical fields, with multiple patents in translational medicine and cancer diagnostics.
-
Published research in high-impact international journals including Biomolecules and Cancers.
-
Served Top 10 global pharmaceutical companies, including Roche, Novartis, Sandoz, and Alcon.
-
Contributed to the successful listing of YD Bio on the Nasdaq Global Market in 2025.
Entrepreneurial Ventures
YD Bio Limited (Nasdaq: YDES) is a Nasdaq-listed international biotechnology company, with its core team and technology originating from Yong Ding Biopharm Co., Ltd., founded in Taiwan in 2013. Headquartered in North America with a global holding structure, YD Bio focuses on cancer early detection, ophthalmic regenerative medicine, and exosome-based therapeutics — driven by a mission to make innovative healthcare more accessible.
Focused on cell therapy and immunotherapy R&D, JY BioMed's platform spans dendritic cell cancer vaccines, γδ T cells, natural killer (NK) cells, mesenchymal stem cells, exosomes, and an anti-CEACAM6 antibody-drug conjugate (ADC), targeting cancer, chronic inflammation, and degenerative diseases.
With a CAP-accredited, CLIA-certified laboratory in Bothell, Washington, EG BioMed is positioned to deliver advanced cancer diagnostic services across the U.S. market.
Philanthropy and Leadership
YuDing Global Cancer Research Foundation
Awarded US$25,000 in research grants since 2022.
Taiwan Chronic Disease Healthcare Association
Established in 2016, the association brings together physicians, pharmacists, nurses, and other healthcare professionals, committed to advancing chronic disease care and health education.